Longeveron (LGVN) AI Stock Analysis

• Market Cap: $16.12M
• Dividend Yield: N/A
• Average Volume (3M): 375.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: 68.67%
• EPS Growth: 85.44%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 19,576,923
• 10 Day Avg. Volume: 298,001
• 30 Day Avg. Volume: 375,497
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 4.98
• Enterprise Value/Gross Profit: 6.32
• Enterprise Value/Ebitda: -0.55
• 1Y Price Target: $3.50
• Price Target Upside: 343.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 44 Neutral
• Price Target: $1.00 ▲(26.58% Upside)

Longeveron's overall stock score is primarily impacted by its financial performance, which shows significant challenges with declining revenues and persistent losses. Technical analysis further indicates bearish momentum. While the earnings call highlighted strategic progress, financial uncertainties and increased expenses weigh heavily on the score.

Positive Factors

Regulatory Progress

FDA's pivotal designation for ELPIS II accelerates regulatory approval, enhancing Longeveron's market position and potential revenue streams.

Pipeline Expansion

Expanding the pipeline with FDA-approved trials for new conditions strengthens Longeveron's long-term growth prospects and competitive edge.

Strategic Manufacturing Partnership

Partnering with a CDMO enhances manufacturing capabilities, supporting scalability and readiness for potential product commercialization.

Negative Factors

Decreased Revenue

Declining revenue reflects challenges in demand and operational execution, potentially hindering financial sustainability and growth.

Increased Operational Expenses

Rising expenses without corresponding revenue growth could strain cash flow and impact profitability, limiting strategic flexibility.

Regulatory and Financial Uncertainty

Uncertainty around regulatory programs and financing poses risks to Longeveron's strategic initiatives and long-term financial health.

Longeveron Business Overview & Revenue Model

Company Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

How the Company Makes Money

Longeveron generates revenue primarily through the development and commercialization of its cellular therapies. The company conducts clinical trials to advance its product candidates, which can lead to partnerships with larger pharmaceutical companies for further development and distribution. Additionally, Longeveron may receive funding through government grants or collaborations for research and development efforts. Key revenue streams include potential product sales from successful clinical trials, licensing agreements, and partnerships that may provide milestone payments and royalties based on future sales of its therapies.

Longeveron Financial Statement Overview

Summary

Longeveron faces significant financial challenges with declining revenues and persistent losses impacting profitability. Despite a high gross profit margin and low leverage, negative cash flows and return on equity highlight ongoing operational and financial difficulties.

Income Statement

Longeveron shows a declining revenue trend with a negative revenue growth rate of -6.83% in the TTM. The company has consistently negative net profit margins, indicating ongoing losses. Gross profit margins are relatively high at 78.77%, but the negative EBIT and EBITDA margins highlight significant operational challenges.

Balance Sheet

The company's debt-to-equity ratio is low at 0.05, indicating minimal leverage, which is a positive aspect. However, the return on equity is significantly negative at -95.90%, reflecting poor profitability relative to shareholder equity. The equity ratio stands at 75.57%, suggesting a strong equity base relative to total assets.

Cash Flow

Longeveron has negative operating cash flow and free cash flow, with a declining free cash flow growth rate of -8.43% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is close to 1, suggesting that cash flow is closely aligned with net income, albeit negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.07M	2.39M	709.00K	1.22M	1.31M	5.63M
Gross Profit	1.63M	1.88M	221.00K	497.00K	590.00K	1.83M
EBITDA	-18.61M	-15.56M	-20.06M	-17.15M	-16.18M	-2.93M
Net Income	-18.54M	-15.97M	-21.41M	-18.84M	-17.05M	-3.72M
Balance Sheet
Total Assets	16.75M	25.56M	12.08M	27.41M	42.77M	9.24M
Cash, Cash Equivalents and Short-Term Investments	10.33M	19.23M	5.36M	19.66M	35.04M	815.80K
Total Debt	639.00K	1.45M	2.04M	2.60M	3.14M	4.14M
Total Liabilities	4.09M	3.67M	5.34M	6.91M	5.31M	7.28M
Stockholders Equity	12.66M	21.89M	6.74M	20.50M	37.45M	1.96M
Cash Flow
Free Cash Flow	-14.27M	-14.86M	-19.70M	-14.82M	-10.95M	-2.63M
Operating Cash Flow	-14.51M	-13.87M	-19.00M	-13.97M	-9.64M	-2.36M
Investing Cash Flow	-1.01M	-640.00K	8.19M	-677.00K	-10.70M	-261.50K
Financing Cash Flow	13.48M	28.79M	5.26M	-509.00K	45.17M	1.58M

Longeveron Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGVN, the sentiment is Neutral. The current price of 0.79 is above the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.94, and below the 200-day MA of 1.38, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 45.61 is Neutral, neither overbought nor oversold. The STOCH value of 34.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LGVN.

Longeveron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OVID	54 Neutral	$116.62M	―	-52.77%	―	1071.91%	-27.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LGVN	44 Neutral	$16.12M	―	-134.50%	―	68.67%	85.44%
PASG	44 Neutral	$25.12M	―	-88.27%	―	―	32.57%
NNVC	42 Neutral	$24.93M	―	-99.75%	―	―	9.49%
CALC	39 Underperform	$42.62M	―	-209.36%	―	―	15.19%
CMMB	33 Underperform	$13.97M	―	-120.76%	―	―	47.86%

Longeveron Corporate Events

Longeveron Announces Leadership Changes Amidst CEO Departure

On August 27, 2025, Longeveron Inc. announced a leadership change with CEO Wa’el Hashad stepping down to pursue other opportunities. Than Powell, the current Chief Business Officer, was appointed as interim CEO effective September 4, 2025. Dr. Joshua Hare, the company’s founder and Chief Science Officer, was appointed as Executive Chairman of the Board. This transition occurs as Longeveron continues to advance its stem cell therapy pipeline, with pivotal Phase 2b clinical trials underway for laromestrocel, and plans for a national search to identify a permanent CEO. The company remains focused on leveraging its stem cell technology to benefit patients and shareholders.

Longeveron Closes $5 Million Public Stock Offering

On August 8, 2025, Longeveron announced the pricing of a public offering of its Class A common stock, which closed on August 11, 2025. The offering, managed by H.C. Wainwright & Co., is expected to generate approximately $5 million upfront, with an additional potential $12.5 million from short-term warrants. The proceeds will support the development of laromestrocel for various conditions and regulatory activities.

Longeveron Gains FDA Approval for Laromestrocel Trial

On July 8, 2025, Longeveron Inc. announced that the U.S. FDA has approved their Investigational New Drug application for laromestrocel, allowing the company to initiate a Phase 2 pivotal registration clinical trial for treating pediatric dilated cardiomyopathy (DCM). This approval marks a significant milestone in pediatric cardiovascular treatment, as current options are limited and often result in heart transplants or death for nearly 40% of affected children. The trial is expected to begin in the first half of 2026, and laromestrocel’s potential to repair damaged heart tissue could be groundbreaking for pediatric cardiovascular diseases.

Longeveron Elects New Director at Annual Meeting

On June 13, 2025, Longeveron held its annual stockholders’ meeting where three key proposals were voted on. The stockholders elected Rock Soffer as a Class I director for a three-year term, approved an amendment to the 2021 Incentive Award Plan to increase authorized shares, and ratified CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal 2025.